- |||||||||| milatuzumab (IMMU-115) / Gilead
Mechanistic and Druggable Landscape of Liver Transplant (LT) Rejection (115-ABC, Level 1) - May 6, 2024 - Abstract #ATC2024ATC_1921;
Immune synapses between T-cells and antigen presenting cells characterize early ACR after LT. Inhibition of antigen presentation by proteasomal inhibitors requires further study as potentially novel treatment of ACR.
- |||||||||| milatuzumab (IMMU-115) / Gilead
Phase classification: Phase Ib Study of SC Milatuzumab in SLE (clinicaltrials.gov) - Aug 19, 2021
P1, N=22, Completed,
The ADC associating trastuzumab and RSL3 may therefore offer potential applications in vectorized therapy alone or in combination with conventional chemotherapies. Phase classification: P1/2 --> P1
- |||||||||| milatuzumab (IMMU-115) / Gilead
Trial completion: Phase Ib Study of SC Milatuzumab in SLE (clinicaltrials.gov) - Feb 4, 2021
P1/2, N=22, Completed,
No abstract available Recruiting --> Completed
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] Mimicking Cytokine-driven Key Features of Arthritis Using a Human in Vitro 3D Joint Model (Feed 11) - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_2720;
The results of our study showed that our human in vitro 3D OTM mimics cytokine-driven cell- and matrix-related changes - key features of RA. By combining the components in a 96-well format, we aim to provide a mid-throughput system for preclinical drug screening.
- |||||||||| milatuzumab (IMMU-115) / Gilead
Enrollment change, Trial termination: Phase I Study of Milatuzumab for Graft Versus Host Disease (clinicaltrials.gov) - Sep 23, 2020
P1, N=12, Terminated,
By combining the components in a 96-well format, we aim to provide a mid-throughput system for preclinical drug screening. N=40 --> 12 | Active, not recruiting --> Terminated; PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD no further patients would be enrolled
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] MIMICKING ARTHRITIS IN VITRO TO TEST DIFFERENT TREATMENT APPROACHES (Poster Tour) - Mar 4, 2020 - Abstract #EULAR2020EULAR_507;
The results of our study showed cytokine related effects of both tissue components, which can be therapeutically antagonized. By combining the components in a 96 well format, we aim to provide a mid-throughput system for preclinical drug testing.
- |||||||||| Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
Journal: Emerging immune targets for the treatment of multiple myeloma. (Pubmed Central) - May 15, 2019
No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab...A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.
- |||||||||| milatuzumab (IMMU-115) / Gilead
Enrollment closed: Phase I Study of Milatuzumab for Graft Versus Host Disease (clinicaltrials.gov) - Mar 3, 2015
P1, N=40, Active, not recruiting,
The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising. Recruiting --> Active, not recruiting
- |||||||||| milatuzumab (IMMU-115) / Gilead
Enrollment open, Trial initiation date, Trial primary completion date: Phase Ib Study of SC Milatuzumab in SLE (clinicaltrials.gov) - Jan 13, 2015
P1/2, N=30, Recruiting,
Trial primary completion date: Jan 2015 --> Jan 2016 Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Jan 2015 | Trial primary completion date: Aug 2015 --> Jan 2017
- |||||||||| milatuzumab (IMMU-115) / Gilead
Trial initiation date: Phase Ib Study of SC Milatuzumab in SLE (clinicaltrials.gov) - Mar 3, 2014
P1/2, N=30, Not yet recruiting,
Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Jan 2015 | Trial primary completion date: Aug 2015 --> Jan 2017 Initiation date: Aug 2013 --> Aug 2014
|
